1 / 18

Cadila Healthcare Ltd

Cadila Healthcare Ltd. Investor Presentation February 2009. ZYDUS CADILA - SNAPSHOT. Ranked 5th in Indian formulations market. (ORG IMS MAT Dec-08). Formulations exports grew by ~70% in last 4 years. Market leader in niche consumer healthcare business with strong brands

damian
Download Presentation

Cadila Healthcare Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cadila Healthcare Ltd Investor Presentation February 2009

  2. ZYDUS CADILA - SNAPSHOT • Ranked 5th in Indian formulations market. (ORG IMS MAT Dec-08). • Formulations exports grew by ~70% in last 4 years. • Market leader in niche consumer healthcare business with strong brands • Focusing on R&D – spending 6-7% of revenues p.a. • Rs. Mio.FY 07-08FY 06-07% Growth Consol. Revenues 23,254 18,289 27% Consol. Operating PAT 2,527 2,063 23%

  3. STATE OF THE ART FACILITIESAND INFRASTRUCTURE • Formulations – four manufacturing plants • Moraiya (Gujarat) - Largest integrated facility in Asia • Baddi (Himachal Pradesh) and Sikkim – for domestic market • Goa – for semi regulated markets • Consumer Products • Moraiya (Gujarat) – for Nutralite • APIs and Fine Chemicals – three plants • Ankleshwar and Dabhasa (Gujarat) • Fine chemicals facility at Ahmedabad (Gujarat) • Contract Manufacturing • Mumbai – for Pantoprazole intermediates for Zydus Nycomed JV • Ahmedabad – for cytotoxic injectibles for Zydus Hospira JV • Ahmedabad – for cytotoxic facility for Zydus BSV JV

  4. CORE BUSINESS AREAS AND REVENUE BREAK-UP (FY 07-08) Revenue break-up by segment Revenue break-up by region

  5. FINANCIAL HIGHLIGHTS • 27% • 31% • 21% • 23% • 23% • 23% • 24% • 24% Note : Operating Net Profit = Net Profit - Exceptional Items - Non Operating Items - Non Operating Forex Gains / Losses

  6. OUR VISION Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.

  7. INDIA FORMULATIONS – SHIFT OF FOCUS Portfolio shift from acute to life style and chronic segments 2007-08 2000-01

  8. ACHIEVEMENTS IN INDIAN MARKET • Zydus Cadila ranks 5th with Rs ~12bn sales. (Source: ORG IMS MAT Dec-08) • Leading positions in the key therapeutic segments – Cardiovascular, Gastrointestinal, Female Healthcare and Respiratory (participated market segments, as per ORG IMS MAT Dec-08) • 14 Zydus brands feature amongst the top 300 brands. (Source: ORG IMS MAT Dec-08) • Exploring opportunities in rural market – next growth driver • Launched >40 new products and line extensions so far in FY 08-09, of which 15 were 1st in India. • Entered dermatology market thru acquisition of Liva Healthcare • Strengthened position in Neutraceuticals,Orthopedic, Diagnostics and Cosmetology segments by adding devoted task forces

  9. INTERNATIONAL FORMULATIONS - TWO FOLD FOCUS • Developed generics markets • US - the largest generic market • Zydus Pharmaceuticals USA Inc. • Europe - Zydus France SAS • Laboratories Combix, Spain • Japan- • Nippon Universal Pharmaceuticals Ltd. • Emerging markets • Brazil – Nikkho (Branded), Zydus Brazil (Generics) • Asia Pacific- Sri Lanka, Myanmar, Taiwan, Philippines • Africa, Middle East – South Africa (Simayla), Sudan, Uganda, Algeria • CIS - Russia , Ukraine International sales projections Formulations-emerging markets Formulations- developed markets APIs/intermediates- exports 2007-08 US$ 217 Mio 2010-11 E US$ 450 Mio

  10. US – MARKETING PLAN AND ACHIEVEMENTS SO FAR • ANDAs approved represent > $ 20 bn market size • Almost half of the products envisage own API. • Plan to file 12-15 ANDAs p.a. • Launched 22 products. Plan to launch 8-10 products every year. • Market share ranges between 5-25% in these products. • Sales ~$ 79 Mio. (CY 2008) • Rated as one of the fastest growing generic companies in US by IMS Robust regulatory pipeline

  11. EUROPE – KEY INITIATIVES SO FAR • New Markets • Entered Spanish market (5th largest in Europe) by acquiring Laboratories Combix • Planning to enter select other markets • Product Launches • Launched >100 generic presentations in France • Plan to launch of 12-15 products p.a. in France • Focus on Generics • Over 2% share in the participated French market. • Rated fastest growing generic company in France (Source : IMS) Leveraging India’s lower cost Generics to drive our French business 29.0 21.8 11.5

  12. EMERGING GLOBAL MARKETS • Presence in over20 semi / non regulated emerging markets. • Amongst top 3 Indian pharma cos. in Sri Lanka, Myanmar, Uganda and Sudan. • Focusing and developing base in rapidly growing markets of Brazil, Russia and Japan. • Forayed into fast growing branded generics market of Brazil thru acquisition of Nikkho do Brazil Ltda. • Acquired Nippon Universal Pharma. Ltd. in 2007-08 to gain entry in Japan. • Recently acquired 70% stake in Simayla Pharma, South Africa. • Exports to these markets grew by >50% in last 3 years and crossed Rs.2 bn mark in FY07-08.

  13. CONSUMER HEALTHCARE – BUILDING STRONG BRANDS • Presence in low calorie sweetener and skincare products business in India since more than 15 years. • Sugar Freegroup - the healthier alternative to sugar • Market leader in India with market share of >75% (AC Nielsen). • Growing at CAGR of over 20% for last 3 years, the brand crossed Rs. 650 Mio. sales mark in FY 07-08. • Everyuthrange of skincare products have also been growing at CAGR of ~ 20% for last 3 years. • Acquired stake in Carnation Nutra-Analogue Foods Ltd., the manufacturers of Nutralite, India’s largest selling margarine • Revamped brand Nutralite post acquisition, which crossed sales Rs. 550 Mio. with 32% growth and registered positive bottom-line in FY 07-08. • Restructuring of consumer business, with de-merger of consumer business from Cadila in Carnation, which is now Zydus Wellness Ltd., is aimed at unlocking business synergies and shareholders’value.

  14. CONTRACT MANUFACTURING - EXCITING PROSPECTS • Zydus Nycomed JV - benchmark in contract manufacturing • Plan to expand scope of the JV • Transfer of current API production of Nycomed over next 2-3 years. • Zydus Hospira - JV for oncology injectables (Generics) • Set up cytotoxic facility located in an SEZ near Ahmedabad. • Commercial production to start from Q1 FY 09-10 • Full capacity utilisation by FY 10-11. • Zydus BSV - JV for oncology NDDS • Mfg. plant in SEZ near Ahmedabad nearing completion. • Launched NDDS product in India in 2008 as Nudoxa • 33 other contracts with innovator and generic MNCs with peak revenue potential of US$ 45 Mio.

  15. RESEARCH FOCUS Scientific Talent Pool ~ 800 • Zydus Research Centre (ZRC) • Located in Ahmedabad • Focused on NME Research & NDDS • Pharmaceutical Technology Centre (PTC) • 2 centers – one located in Ahmedabad, another in Mumbai • Focused on Finished Dosage Form Development & NDDS R&D Spends – FY 07-08 62% • API Process Research • Located in Ankleshwar/Ahmedabad • Focused on Process Development 32% 6% Rs. 1,588 Mio. (~ $ 39 Mio.) (~7% of revenues)

  16. ZYDUS RESEARCH CENTER - INVESTING FOR THE FUTURE • NME Research, Biologicals (Biogenerics) & NDDS. • Therapeutic Area: Dyslipidemia, Diabetes, Obesity, Inflammation. • Infrastructure for target identification to pre-clinical research / early clinical development. • Multiple candidates under preclinical stage. NME Pre Clinical IND Filing Phase 1 Phase 2 Phase 3 NME Pipeline ZYH1 Dyslipidemia ZYI1 Inflammation ZYH2 Diabetes ZY01 Obesity ZYH7 Dyslipidemia ZYT1 Dyslipidemia

  17. HIGHLIGHTS FROM LATEST FINANCIAL RESULTS Note : Operating Net Profit = Net Profit - Exceptional Items - Non Operating Items - Non Operating Forex Gains / Losses

  18. Thank You. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.. This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements.The Company also disclaims any obligation to revise any forward-looking statements . The viewers may use their own judgement and are advised to make their own calculations before deciding on any matter based on the information given herein www.zyduscadila.com

More Related